Prognostic value of CEA and ferritin assay in breast cancer: A multivariate analysis

Gaglia, P; Caldarola, B; Bussone, Riccardo; Potente, F; Lauro, Danilo; Jayme, Augusto; Caldarola, L

doi:10.1016/0277-5379(88)90121-6

Cited by 17 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CEA was also one of the first markers assayed in patients with breast cancer, but now, due to its low sensitivity and specificity, the National Academy of Clinical Biochemistry (NACB) and the European Group on Tumor Markers (EGTM) do not recommend its determination in these patients [ 27 , 28 ]. However, the build-up of CEA levels is observed in breast cancer patients with more advanced disease, and its elevated values prior to treatment are not considered to be an important prognostic factor [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

et al. 2016

View full text Add to dashboard Cite

An attempt was made to compare the usefulness of determining markers carcinoembryonic antigen (CEA) and tumor-associated trypsin inhibitor (TATI) in endometrial cancer patients in whom recurrence or distant metastasis was diagnosed in observation after treatment. The study included 316 patients aged 32–81, average age of 61 years, SD = 8.72, with diagnosed endometrial cancer, treated between 1994 and 1995 at the Oncology Center in Warsaw and then under observation from 4 months to 17 years after completion of treatment. The levels of the markers TATI and CEA were assessed from the first five serum samples taken during postoperative radiotherapy and in the initial period of observation after completed treatment. Receiver operating characteristic (ROC) curves were generated, determining the sensitivity and specificity of both CEA and TATI in patients who experienced treatment failure, i.e., recurrence and distant metastasis. Assessing the sensitivity of the marker CEA, it was found that if in the third sample, i.e., during radiation therapy, the marker level increased by more than 20 % compared with the first sample, then recurrence of cancer occurred during the observation period in 75.9 % of patients and metastatic occurred in 69.7 % of patients. In the evaluation of the marker TATI, it was found that if the level of TATI between the first and the third sample increases by 10.6 % from the initial level, then in 84.4 % (sensitivity) of cases, this means the occurrence of cancer recurrence and in 75.7 % (sensitivity) of cases, the occurrence of metastasis. The specificity of both markers is low and not useful diagnostically.

show abstract

Section: Discussionmentioning

confidence: 99%

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, in case of symptomatic BC patients CEA sensitivity increases, and some authors evidenced that CEA levels at diagnosis are able to correlate with the stage of disease [39, 40]. Additionally, as a prognostic tool, the positive pretherapeutic levels of CEA may be useful to highlight those patients with a worse prognosis and at risk to have a recurrence after primary therapy [41, 42]. …”

Section: Tumor Markers For Diagnosis and Prognosis Of Bcmentioning

confidence: 99%

Usefulness of Traditional Serum Biomarkers for Management of Breast Cancer Patients

Mirabelli

Incoronato

2013

BioMed Research International

View full text Add to dashboard Cite

The measurement of serum tumor markers levels in breast cancer (BC) patients is an economic and noninvasive diagnostic assay frequently requested by clinical oncologists to get information about the presence or absence of disease as well as its evolution. Despite their wide use in clinical practice, there is still an intense debate between scientific organizations about the real usefulness for patient monitoring during followup as well as response to therapy evaluation in case of advanced BC. In this review, we want to highlight the current recommendations published by scientific organizations about the use of “established” BC serum markers (CEA, TPA, TPS, CIFRA-21, CA15-3, and s-HER2) in clinical oncology practice. Moreover, we will focus on recent papers evidencing the usefulness of tumor markers levels measurement as a guide for the prescription and diagnostic integration of molecular imaging exams such as those performed by hybrid 18-fluorofeoxyglucose-positron emission tomography with integrated computed tomography. This technology is nowadays able to detect early cancer lesions undetectable by conventional morphological imaging investigation and most likely responsible for increasing of serum tumor markers levels.

show abstract

“…CEACAM5 is consistently overexpressed in various malignancies frequently associated with poor patients' clinical outcome and reduced overall survival (Chevinsky 1991). These properties have made CEACAM5 a prominent clinical cancer biomarker, widely used in early diagnosis, effective prognosis, and monitoring of colon cancer, as well as other types of cancers (Gaglia et al 1988;Ballesta et al 1995).…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family

Pavlopoulou

Scorilas

2014

Genome Biology and Evolution

View full text Add to dashboard Cite

The carcinoembryonic antigen (CEA) gene family belongs to the immunoglobulin (Ig) superfamily and codes for a vast number of glycoproteins that differ greatly both in amino acid composition and function. The CEA family is divided into two groups, the carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) and the pregnancy-specific glycoproteins. The CEA family members are implicated in pleiotropic (patho)physiological functions including cell–cell adhesion, pregnancy, immunity, neovascularization, regulation of insulin homeostasis, and carcinogenesis. In general, the CEA-encoded proteins are composed of an extracellular region with Ig variable and constant-like domains and a cytoplasmic region containing signaling motifs. Of particular interest, the well-studied human and mouse CEA genes are arranged in clusters in a single chromosome. Taking into account this characteristic, we made an effort to reconstruct the evolutionary history of the CEA gene family. Toward this end, the publicly available genomes were searched extensively for CEA homologs. The domain organization of the retrieved protein sequences was analyzed, and, subsequently, comprehensive phylogenetic analyses of the entire length CEA homologous proteins were performed. A series of evolutionarily conserved amino acid residues, functionally important, were identified. The relative positioning of these residues on the modeled tertiary structure of novel CEA protein domains revealed that they are, also, spatially conserved. Furthermore, the chromosomal arrangement of CEA genes was examined, and it was found that the CEA genes are preserved in terms of position, transcriptional orientation, and number in all species under investigation.

show abstract

Prognostic value of CEA and ferritin assay in breast cancer: A multivariate analysis

Cited by 17 publications

References 13 publications

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

Usefulness of Traditional Serum Biomarkers for Management of Breast Cancer Patients

A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family

Contact Info

Product

Resources

About